Sunday 18 October 2026
Export AVLN’s income statement to Excel — free account
Avalyn Pharma Inc.
AVLN
Insiders bought in the last twelve months.
23.66
0.98
−3.98%
Follow AVLN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 51 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | — | — | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| Net income | — | — | — | — | — | — | — | — | — | 0 | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Earnings | — | — | — | — | — | — | — | — | — | — | |||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Book value | — | — | — | — | — | — | — | — | — | — | |||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | ||||
| ROIC | — | — | — | — | — | — | — | — | — | — | |||||
| ROE | — | — | — | — | — | — | — | — | — | — | |||||
Negative figures in brackets.